ReviewDer Internist2010
[Sjögren syndrome].
Review in Der Internist, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- The Diagnosis and Treatment of Sjögren's Syndrome.Deutsches Arzteblatt international · 2017Review
- Acute transverse myelitis and psoriasiform dermatitis associated with Sjoegren's syndrome: a case report.BMC research notes · 2014Article
- Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.International journal of clinical rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's syndrome (SS) is a chronic inflammatory disorder of hitherto unknown origin. The characteristic hallmark of SS is focal lymphocytic infiltration and slow destruction of exocrine glands, such as lacrimal and salivary glands. Sicca symptoms and/or recurrent parotid gland swelling are often accompanied by fatigue. Clinically relevant extraglandular manifestations occur in more than 20% of patients with primary SS. The development of malignant B cell lymphoma is the most important complication, which affects about 5% of primary SS patients who are at higher risk to develop malignant B cell lymphoma, both when compared with the general population as well as with patients with SS secondary to other systemic autoimmune disorders. Treatment of sicca symptoms is primarily symptomatic, whereas glucocorticoids, NSAIDs and/or immunosuppressive drugs may be indicated for the treatment of extraglandular manifestations. New therapeutic strategies, such as B cell targeted therapies, are in clinical testing especially for patients with severe organ manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.